Page 3 - Fusion Polypeptides News Today : Breaking News, Live Updates & Top Stories | Vimarsana

expected beyond 2023 CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs. “Over the course of the first quarter, we continued to execute on our key strategic priorities by significantly st...

expected beyond 2023 CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- AEterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs. “Over the course of the first quarter, we continued to execute on our key strategic priorities by significantly stre...